The Biggest Indian Pharma Deal of the Decade

The multinational is giving way to the multi-local, as tariffs, geopolitics and supply-chain risk force companies to rebuild around regional roots rather than one global blueprint. In the latest Corner Office Conversation from The Economic Times World Leaders Forum Bain & Company ...  Show more

Chhattisgarh has declared an end to armed Maoism in Bastar, but the ground reality is far more complicated than a deadline. Over 1,000 surrendered cadres remain in rehabilitation centres while 1,800 others have already returned to their villages — some welcomed, others met with d ...  Show more

(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. \u0010 \u0010GUEST: \u0010Cynthia Koons \u0010Health Care Reporter \u0010Bloomberg Editorial \u0010on Pfizer beating out rivals to buy biopharmaceutical company, Medivation, and its blockbuster cancer drug for $14 billi ...  Show more

In the past month pharmaceutical companies have spent almost $100bn acquiring biotech companies. The FT's Sarah Neville explains why big pharma is raising its bet on the drug pipelines owned by biotechs, and why analysts expect more consolidation in 2019. 

Read ...

Bloomberg’s Caroline Hyde and Ed Ludlow discuss Electronic Arts’ agreement to be sold in a record-breaking leveraged buyout. Plus, Huawei plans to ramp up production of its most advanced AI chips in a bid to take market share from Nvidia. And Peloton is preparing to launch new AI ...  Show more

Jim Cramer and David Faber breakdown M&A Monday. A busy morning in deal news, starting with a historic deal in the chip sector. Nvidia buying Arm from Softbank in a deal valued at $40 billion financed through a combination of cash and common stock. Nvidia CEO, Jensen Huang, jo ...